International Agency for Research on Cancer, Lyon, France.
Brain Pathol. 2010 Sep;20(5):936-44. doi: 10.1111/j.1750-3639.2010.00395.x. Epub 2010 Mar 18.
Glioblastomas are morphologically and genetically heterogeneous, but little is known about the regional patterns of genomic imbalance within glioblastomas. We recently established a reliable whole genome amplification (WGA) method to randomly amplify DNA from paraffin-embedded histological sections with minimum amplification bias [Huang et al (J Mol Diagn 11: 109-116, 2009)]. In this study, chromosomal imbalance was assessed by array comparative genomic hybridization (CGH; Agilent 105K, Agilent Technologies, Santa Clara, CA, USA), using WGA-DNA from two to five separate tumor areas of 14 primary glioblastomas (total, 41 tumor areas). Chromosomal imbalances significantly differed among glioblastomas; the only alterations that were observed in > or =6 cases were loss of chromosome 10q, gain at 7p and loss of 10p. Genetic alterations common to all areas analyzed within a single tumor included gains at 1q32.1 (PIK3C2B, MDM4), 4q11-q12 (KIT, PDGFRA), 7p12.1-11.2 (EGFR), 12q13.3-12q14.1 (GLI1, CDK4) and 12q15 (MDM2), and loss at 9p21.1-24.3 (p16(INK4a)/p14(ARF)), 10p15.3-q26.3 (PTEN, etc.) and 13q12.11-q34 (SPRY2, RB1). These are likely to be causative in the pathogenesis of glioblastomas (driver mutations). In addition, there were numerous tumor area-specific genomic imbalances, which may be either nonfunctional (passenger mutations) or functional, but constitute secondary events reflecting progressive genomic instability, a hallmark of glioblastomas.
胶质母细胞瘤在形态学和遗传学上具有异质性,但对胶质母细胞瘤内基因组失衡的区域模式知之甚少。我们最近建立了一种可靠的全基因组扩增 (WGA) 方法,可最小化扩增偏差,从石蜡包埋的组织切片中随机扩增 DNA [Huang 等人,(J Mol Diagn 11:109-116,2009)]。在这项研究中,通过阵列比较基因组杂交 (CGH; Agilent 105K,Agilent Technologies,Santa Clara,CA,USA) 评估染色体失衡,使用来自 14 例原发性胶质母细胞瘤的 2 到 5 个不同肿瘤区域的 WGA-DNA(总共 41 个肿瘤区域)。胶质母细胞瘤之间的染色体失衡明显不同;观察到 > 或 = 6 例的唯一改变是 10q 染色体缺失、7p 增益和 10p 缺失。在单个肿瘤内分析的所有区域中共同的遗传改变包括 1q32.1(PIK3C2B、MDM4)、4q11-q12(KIT、PDGFRA)、7p12.1-11.2(EGFR)、12q13.3-12q14.1(GLI1、CDK4)和 12q15(MDM2)的增益,以及 9p21.1-24.3(p16(INK4a)/p14(ARF))、10p15.3-q26.3(PTEN 等)和 13q12.11-q34(SPRY2、RB1)的缺失。这些可能是胶质母细胞瘤发病机制中的致病因素(驱动突变)。此外,还有许多肿瘤区域特异性的基因组失衡,这些失衡可能是非功能性的(乘客突变)或功能性的,但构成了反映基因组不稳定性进展的次要事件,这是胶质母细胞瘤的一个标志。